OHSU

IRB #

IRB00008787

Title

A Phase 2 Study of Increased-Dose Abiraterone Acetate in Patients with Castration Resistant Prostate Cancer (CRPC)

Principal Investigator

Julie Graff

Study Purpose

To find out how effective, an increased dose of the study drug (Abiraterone Acetate) and prednisone are against prostate cancer, based on time to prostate-specific antigen (PSA) progression, and/or progression by imaging (CT scan, bone scan) and, to find out the side effects of the study drug.

Medical Condition(s)

Metastatic Castrate Resistant Prostate Cancer

Eligibility Criteria

* Subjects must have prostate cancer which has spread outside the prostate and is progressing by PSA.
* Subjects have not had any chemotherapy.
* Subjects should not have history of pituitary or adrenal dysfunction.

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

Minors Included

No

Contact

Clinical Trials Information Line: Phone 503-494-1080 or trials@ohsu.edu

Sponsor

UCSF Helen Diller Family Comprehensive Cancer Center

Recruitment End

Compensation Provided

No


Go Back